Join The Clearity Foundation for an interactive discussion with Dr. George Poste about oncology at the forefront of healthcare’s evolution into an era of precision medicine. With predicted increases in cancer treatment costs, rational treatment selection using molecular diagnostics represents a major opportunity to contain healthcare spending. However, regulatory and reimbursement uncertainty, clinical trial design and expense, physician adoption and patient awareness represent significant challenges to a rapidly evolving field. Clearity welcomes you to join the conversation with one of healthcare’s esteemed thought leaders.

Tuesday, October 8, 2013
Goldberg Auditorium at Moores Cancer Center
3855 Health Sciences Drive
La Jolla, CA 92093
5:00 – 8:00pm
$75 registration
RSVP: Please email patpio@clearityfoundation.org
Twitter: #pmsymposium

Dr. George Poste is Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative (http://www.casi.asu.edu) at Arizona State University (ASU). His research links molecular diagnostics and high performance computing to study the altered regulation of molecular networks in human diseases. He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his research contributions. He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences, and Advisory Boards for Burrill and Company and Synthetic Genomics. He is a Fellow of the U.K. Royal Society and Academy of Medicine, member of the Council for Foreign Relations and the U. S. Institute of Medicine Board on Global Health. He currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.